We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Thoratec could lose its dominance in the U.S. left-ventricular assist device (LVAD) market this year if the FDA approves competitor Heartware’s LVAD pump, analysts say.